Clinical Events in High-Risk Hypertensive Patients Randomly Assigned to Calcium Channel Blocker Versus Angiotensin-Converting Enzyme Inhibitor in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial

Leenen, Frans H.H.; Nwachuku, Chuke E.; Black, Henry R.; Cushman, William C.; Davis, Barry R.; Simpson, Lara M.; Alderman, Michael H.; Atlas, Steven A.; Basile, Jan N.; Cuyjet, Aloysius B.; Dart, Richard; Felicetta, James V.; Grimm, Richard H.; Haywood, L. Julian; Jafri, Syed Z.A.; Proschan, Michael A.; Thadani, Udho; Whelton, Paul K.; Wright, Jackson T.

doi:10.1161/01.hyp.0000231662.77359.de

Clinical Events in High-Risk Hypertensive Patients Randomly Assigned to Calcium Channel Blocker Versus Angiotensin-Converting Enzyme Inhibitor in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial

The Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT) provides a unique opportunity to compare the long-term relative safety and efficacy of angiotensin-converting enzyme inhibitor and calcium channel blocker–initiated therapy in older hypertensive individuals. …